Is quantitative benefit–risk modelling of drugs desirable or possible?
Lawrence D. Phillips(European Medicines Agency), Barbara Fasolo(London School of Economics and Political Science), Nikolaos Zafiropoulos(European Medicines Agency), Andrea Beyer(University Medical Center Groningen)
Cited by 51
Abstract
Related Papers
No related papers found
Powered by citation graph analysis